Screener
AbCellera Biologics Inc. ABCL Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by AbCellera Biologics Inc. in its filing.
Tagged under the XBRL concept us-gaap:EmployeeRelatedLiabilitiesCurrent.
The source filing: AbCellera Biologics Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:28 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001703057-26-000046
| Line item | December 31, 2025 | June 30, 2026 |
|---|---|---|
| Accounts payable and accrued liabilities | $25,228 | $12,107 |
| Current portion of operating lease liability | 5,815 | 5,669 |
| Payroll liabilities | 10,755 | 6,076 |
| Current portion of deferred government contribution | 8,983 | 8,632 |
| Total accounts payable and other current liabilities | $50,781 | $32,484 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is AbCellera Biologics Inc.'s accrued expenses?
- AbCellera Biologics Inc. (ABCL) reported accrued expenses of $6.08M in Q2 2026.
- How has AbCellera Biologics Inc.'s accrued expenses changed year-over-year?
- AbCellera Biologics Inc.'s accrued expenses increased by 22.4% year-over-year, from $4.97M to $6.08M.
- What is the long-term trend for AbCellera Biologics Inc.'s accrued expenses?
- Over 3 years (2022 to 2025), AbCellera Biologics Inc.'s accrued expenses has grown at a 18.6% compound annual growth rate (CAGR), from $6.45M to $10.76M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.
Ask your AI about AbCellera Biologics Inc.'s accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude